Last reviewed · How we verify
HST101
At a glance
| Generic name | HST101 |
|---|---|
| Also known as | Lerodalcibep |
| Sponsor | Hasten Biopharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants (PHASE1)
- A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HST101 CI brief — competitive landscape report
- HST101 updates RSS · CI watch RSS
- Hasten Biopharmaceutical Co., Ltd. portfolio CI